http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2447598-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_34c531b0dce54fb192c75fd1f4f8d473 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P23-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D223-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 |
| filingDate | 2002-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7b807d9251c70975fe63f828c384d22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6997b7dcb2adac753d7cecfa0276678 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a78f2e2ec882defe4af4991e495ac64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3ae879dd2a9216ad72b6158ee4c18b8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3e077d8f7caa48b5955318fe5d421e1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a30553f3801003efe58c1ad7bff5385 |
| publicationDate | 2002-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2447598-A1 |
| titleOfInvention | Use of compounds with combined nep/mp-inhibitory activity in the preparation of medicaments |
| abstract | This invention relates to the use of a compound having combined, in particul ar concurrent, inhibitorz activity on neutral endopeptidase (NEP) and on a nove l metalloprotease designated IGS5, or of a pharmaceutically acceptable salt or solvate or biolabile ester thereof, for the manufacture of a medicament (pharmaceutical composition) for treating a larger mammal, preferably a huma n, suffering from or being susceptible to a disease or condition which can be alleviated or prevented by combined or concurrent inhibition of NEP and IGS5 . In a particular aspect the present invention pertains to the use of said compounds with combined or concurrent NEP/IGS5 inhibitory activity for treating a larger mammal, preferably a human, suffering from or being susceptible to a disease or condition where bit-ET-l levels are elevated and which disease or condition can be alleviated or prevented by cobined or concurrent inhibition of NEP and IGS5. In a further particular aspect the present invention pertainsto the use of said compounds with combined or concurrent NEP/IGS5 inhibitory activity for treating a larger mammal, preferably a human, suffering from or being susceptible to a disease or condition where ET-1 is significantly upregulated and which disease or condition can be alleviated or prevented by combined or concurrent inhibitio n of NEP and IGS5. In the present invention said compounds with combined or concurrent NEP/IGS5-inhibitory activity preferably are used for the treatmen t and/or prophylaxis of hypertension, including secondary forms of hypertensio n such as renal or pulmonary hypertension, heart failure, angina pectoris, arrhythmias, myorcadial infarction, cardiac hypertrophy, cerebral ischemia, peripheral vascular disease, subarachnoidal hemorrhage, chronic obstructive pulmonary disease (COPD), asthma, renal disease, atherosclerosis, and pain i n colorectal cancer or prostate cancer, in mammals, preferably in humans, and more preferably in a patient sub-population suffering from or being susceptible to a disease or condition which can be alleviated or prevented b y combined or concurrent inhibition of NEP and IGS5. Furthermore, it may be beneficial to additionally combine the said compounds showing combined or concurrent NEP/IGS5 inhibitory activity with other individual and/or combine d metalloprotease inhibitors than the NEP/IGS5 inhibitors, e.g. with separate ACE- and/or NEP-inhibitors and/or mixed inhibitors of these metalloproteases . |
| priorityDate | 2001-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 869.